The guidance will help the FDA determine whether citizen petitions and petitions for a stay of agency action are being submitted because a drugmaker wants to slow the approval process of a pending generic or biosimilar, according to Regulatory Focus.
The new guidelines come after the FDA expressed concerns to Congress that petitions are often submitted by competing drug companies and do not raise valid concerns.
The guidelines outline which issues are of valid concern and impose a 150-day deadline to take action on petitions.
The FDA also said it will refer certain issues to the Federal Trade Commission to dissuade drugmakers from improperly using these petitions.
Read the full report here.
More articles on pharmacy:
Carcinogen concerns prompt Sandoz to halt global distribution of heartburn drug
DEA raids some West Coast Kaiser Permanente pharmacies
California biotech files for bankruptcy
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.